MedTrace Logo

mHealth for Pneumonia Prevention

NCT04493047 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 520

Last updated 2024-06-10

No results posted yet for this study

Summary

In Pakistan, pneumonia and recurrent wheeze in children under five pose significant threats to children's health. Despite being preventable, more than 90,000 children die each year due to pneumonia in Pakistan, making it one of the top five countries in the world, with the highest pneumonia related childhood mortality. The predisposing factors which lead to these illnesses include lack of hygiene, lack of immunization, overcrowding, household air pollution, smoking, and poverty. Prompt recognition and timely initiation of treatment is imperative in children under five with pneumonia and recurrent wheeze and failure to do so can lead to complications and death. In children under five, among the causes of death due to these diseases, one is delayed care seeking. It has been identified that around 38% of deaths due to respiratory illnesses occur in households due to this delayed care seeking which is defined as delay in care sought for an illness outside home.

Conditions

Interventions

BEHAVIORAL

Mobile health (mHealth) for pneumonia

Audiovisual mobile based application will be used to counsel caregivers of children under five on pneumonia and its prevention. This will be coupled with text and voice message dissemination to the cell phones of caregivers.

Sponsors & Collaborators

  • Maternal, Neonatal and Child Health Research Network

    collaborator OTHER

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • Dr Tabish Hazir, MBBS, FRCPCH · Maternal, Neonatal and Child Health Research Network

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2020-12-01
Completion
2021-03-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04493047 on ClinicalTrials.gov